Citations

Clear

6274 citation(s) found for "To, Andrew".

The pharmacy residency program guide to Twitter
Webb, Andrew , Margetak, Danielle, Schramm, Garrett E. , Mordino, Jason

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | April 19, 2022 | Volume: 4 | Issue: 4 | Pages: 507-513

10.1002/jac5.1372 Get It

AbstractBackgroundTwitter has emerged as a powerful networking and educational tool within the health care community. The instantaneous and casual nature of Twitter allows for easy access to a near limitless pool of medical professionals and the opportunity to share intra‐ and interprofessional knowledge. Beyond individual development, Twitter has the potential to positively impact pharmacy residency programs in a multitude of ways.ObjectiveThis article serves as a practical guide for pharmacy residency programs to implement and maintain a successful Twitter account.RecommendationsAt the program level, a Twitter account creates an official voice and brand while simultaneously providing detail and perspective beyond what a residency website may offer. Additionally, it allows for dynamic ground‐level engagement with prospective residency candidates, current residents, and preceptors which is mutually beneficial to the program audience. In the age of virtual recruitment, successfully utilizing digital tools to meet candidates where they are is essential for attracting the right candidate for the program. Implementation of a successful social media strategy has potential barriers that include garnering buy‐in from departmental leadership, operationalizing a social media team, and maintaining engagement momentum.ConclusionPharmacy residency programs should consider starting an official Twitter account.
CA9 expression in breast implant‐associated anaplastic large cell lymphoma presenting in a lymph node
Oishi, Naoki , Feldman, Andrew L. , Feldman, Andrew L , Oishi, Naoki

Mayo Clinic

Histopathology | April 19, 2022 | Volume: 81 | Issue: 2 | Pages: 270-272

10.1111/his.14666 | PMID 35437827 Get It

Comparison of Two Diet and Exercise Approaches on Weight Loss and Health Outcomes in Obese Women
Lockard, B , Mardock, M, Oliver, Jonathan M. , Simbo, S, Jagim, Andrew R. , Kresta, Julie, Baetge, Claire, Jung, Y , Koozehchian, M , Khanna, Deepesh , Rasmussen, C, Kreider, Richard B. , Lockard, Brittanie , Jagim, Andrew R , Koozehchian, Majid S , Kreider, Richard B , Byrd, Mike

Mayo Clinic

International Journal of Environmental Research and Public Health | April 18, 2022 | Volume: 19 | Issue: 8 | Pages: 4877

10.3390/ijerph19084877 | PMID 35457744 Get It

Aim: To compare the efficacy of two popular weight loss approaches on weight loss, body composition, and markers of health in sedentary obese women. Methods: In total, 51 sedentary women (age 34.5 ± 7.7 yrs.; weight 90.0 ± 14.5 kg; BMI 34.0 ± 5.1 kg/m2; 46.5 ± 7.0% fat) were matched and randomized to participate in the Weight Watchers® Momentum™ (WW) or Curves® (CV) Fitness and Weight Management program for 16 weeks. Participants in the WW group (n = 27) were provided a point-based diet program, received weekly progress checks and counseling, and were encouraged to exercise. Participants in the CV group (n = 24) followed a menu-based higher protein/low-fat diet (1200 kcal/d) for 1 week; 1500 kcal/d diet for 3 weeks; and 2000–2500 kcals/d for 2 weeks that was repeated three times (except the last segment) while participating in a supervised circuit-style resistance training program (3 d/wk). A general linear model (GLM) with repeated measures was used to analyze data and are presented as mean changes from baseline (mean [UL, LL]). Results: Supervised CV training resulted in greater amounts of vigorous and total physical activity. After 16 weeks, both groups lost weight (WW −6.1 [−7.8, −4.6], CV −4.9 [−6.2, −3.2] kg, p = 0.264). Participants in the CV group observed greater reductions in fat mass (WW −2.9 [−6.7, −0.2], CV −6.4 [−9.2, −3.6] kg, p = 0.081) and increases in lean mass (WW −2.5 [−4.3, −0.7], CV 1.3 [−0.6, 3.2] kg, p = 0.005) resulting in more favorable changes in percent body fat (WW −1.4 [−4.1, 1.2], CV −4.7 [−7.5, −1.8]%, p = 0.098). Both groups observed improvements in peak aerobic capacity and muscular endurance, although bench press lifting volume was greater in the CV group. Those in the CV group experienced a greater increase in HDLc and reduction in the CHL–HDLc ratio and triglycerides. Conclusion: Both interventions promoted weight loss and improvements in fitness and markers of health. The CV program, which included supervised resistance training and higher protein diet menus, promoted greater fat loss, increases in lean mass, and improvements in percent body fat and blood lipids. Trial Registration: clinicaltrials.gov, #NCT04372771, registered retrospectively 1 May 2020.
Perioperative chemotherapy for resectable colorectal liver metastases: Analysis from the Colorectal Operative Liver Metastases International Collaborative (COLOMIC)
Gawdi, Rohin , Moaven, Omeed , Piccolo, Nico R. Del, Corvera, Carlos U. , Wisneski, Andrew D. , Cha, Charles , Russell, Greg, Zarandi, Nima Pourhabibi , Dourado, Justin , Shen, Perry , Moaven, Omeed , Del Piccolo, Nico R, Valenzuela, Cristian D. , Stauffer, John , Cheung, Tan To

Mayo Clinic

Journal of Surgical Oncology | April 16, 2022 | Volume: 126 | Issue: 2 | Pages: 339-347

10.1002/jso.26893 | PMID 35429409 Get It

AbstractBackgroundChemotherapy has been increasingly combined with surgery as multimodality treatment for resectable colorectal‐liver metastases (CLM). There is paucity of clinical data addressing optimal timing of chemotherapy relative to surgery. We examined outcomes of patients undergoing hepatectomy for resectable CLM.MethodsSeven hundred and eighteen patients treated with hepatectomy for CLM were analyzed from five hepatobiliary institutions between 2000 and 2018. Overall survival (OS) was measured from time of hepatectomy for patients receiving: surgery alone, neoadjuvant, adjuvant, and neoadjuvant‐plus‐adjuvant (perioperative) chemotherapy. Kaplan–Meier analysis was performed to detect differences in OS between treatment groups. Single‐ and multi‐variable analysis with Cox proportional hazards were run for OS between groups.ResultsOne hundred and thirty‐seven patients (19.08%) received surgery, 104 (14.48%) received neoadjuvant‐only, 214 (29.81%) received adjuvant‐only, and 263 (36.63%) received perioperative chemotherapy; with median OS of 48.20, 46.83, 56.27, and 49.93 months, respectively. No differences in median OS were seen between groups on Kaplan–Meier analysis. No significant difference in Charlson‐Deyo comorbidity status was seen between groups (p = 0.853), while significant difference was seen in maximum tumor size (p = 0.0023). On multivariate analysis, adjuvant (p = 0.010) and perioperative (p = 0.020) chemotherapy were independently associated with OS compared to surgery alone.DiscussionDespite group differences, chemotherapy after surgery was independently associated with improved OS in CLM.
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States
Ahn, Joseph , Lauzon, Marie , Luu, Michael , Noureddin, Mazen , Ayoub, Walid S. , Kuo, Alexander , Sundaram, Vinay , Kosari, Kambiz , Nissen, Nicholas N. , Hendifar, Andrew , Roberts, Lewis R. , Yang, Ju Dong , Ahn, Joseph C , Singal, Amit , Yang, Ju Dong , Roberts, Lewis R , Gong, Jun , Abou‐Alfa, Ghassan K. , Singal, Amit G.

Mayo Clinic

Hepatology | April 16, 2022 | Volume: 76 | Issue: 6 | Pages: 1649-1659

10.1002/hep.32527 | PMID 35429171 Get It

Abstract Background and Aims Immunotherapy has emerged as an effective treatment for patients with advanced‐stage HCC. We aimed to investigate the efficacy of immunotherapy for advanced HCC in a nationwide cohort and racial and ethnic disparities in access to immunotherapy. Approach and Results We used the US National Cancer Database to identify patients with tumor‐node‐metastasis stage 3 or 4 HCC between 2017 and 2018. We performed multivariable Cox regression to identify factors associated with overall survival (OS) and logistic regression to identify factors associated with receipt of immunotherapy. Of the 3,990 patients treated for advanced HCC, 3,248 (81.4%) patients received chemotherapy and 742 (18.6%) patients received immunotherapy as a first‐line treatment. Immunotherapy was associated with improved OS compared with chemotherapy (adjusted HR: 0.76, 95% CI: 0.65–0.88) after adjusting for covariates. There were racial and ethnic disparities in access to immunotherapy, with Hispanic (adjusted OR [aOR]: 0.63, 95% CI: 0.46–0.83) and Black patients (aOR: 0.71, 95% CI: 0.54–0.89) less likely to receive immunotherapy compared with White patients. There was a significant interaction between race‐ethnicity and facility type, with higher disparity observed in nonacademic centers (interaction p = 0.004). Conclusions Immunotherapy was associated with improved OS compared with chemotherapy in advanced HCC. There are significant disparities in early access to immunotherapy, likely due to differential access to clinical trials and experimental therapies. A comprehensive approach to monitoring and eliminating racial‐ethnic disparities in the management of advanced HCC is urgently needed.
Cardiac Magnetic Resonance at 3.0 T in Patients With C282Y Homozygous Hereditary Hemochromatosis
Byrne, Danielle, Walsh, John P., Murphy, Ross T., McMorrow, Jason, Fagan, Andrew J., Poetrzyk, Aneta Kecler, Durand, Michael E., Norris, Suzanne, McKiernan, Susan, King, Gerard, Meaney, James F., Daly, Caroline, Byrne, Danielle, Walsh, John P., Murphy, Ross T., McMorrow, Jason, Fagan, Andrew J., Poetrzyk, Aneta Kecler, Durand, Michael E., Norris, Suzanne, McKiernan, Susan, King, Gerard, Meaney, James F., Daly, Caroline

Mayo Clinic

Journal of Thoracic Imaging | April 15, 2022 | Volume: 37 | Issue: 5 | Pages: 300-306

10.1097/rti.0000000000000645 | PMID 35426858 Get It

Background: Iron-overload cardiomyopathy initially manifests with diastolic dysfunction and can progress to dilated cardiomyopathy if untreated. Previous studies have shown that patients with primary and secondary hemochromatosis can have subclinical left ventricle dysfunction with abnormalities on strain imaging. This study aimed to evaluate the relationship between cardiac T2* values and myocardial-wall strain in patients with hereditary hemochromatosis (HH) at the time of diagnosis and after a course of venesection treatment. Materials and Methods: Baseline cardiac magnetic resonance (CMR) at 3 T was performed in 19 patients with newly diagnosed HH with elevated serum ferritin levels and repeated after a course of treatment with venesection. Quantitative T2* mapping and strain analysis were performed offline using dedicated relaxometry fitting and feature-tracking software. Results: The majority (84%) of patients had normal baseline myocardial T2* values (mean 19.3 ms, range 8.9 to 31.2 ms), which improved significantly after venesection (mean 24.1 ms, range 11 to 38.1 ms) (P=0.021). Mean global radial strain significantly improved from 25.0 (range: 15.6 to 32.9) to 28.3 (range: 19.8 to 35.8) (P=0.001) and mean global circumferential strain improved, decreasing from −15.7 (range: −11.1 to −19.2) to −17.1 (range: −13.0 to −20.1) (P=0.001). Conclusion: Patients with HH may have normal T2* values in the presence of subclinical left ventricle dysfunction, which can be detected by abnormal radial and circumferential strain. As strain imaging improves following venesection in HH, it may serve as a useful biomarker to guide treatment.
Endoscopic submucosal dissection for colorectal dysplasia in inflammatory bowel disease: a US multicenter study
Ngamruengphong, Saowanee , Aihara, Hiroyuki , Friedland, Shai , Benias, Petros C. , Draganov, Peter V. , Kumta, Nikhil A. , Borman, Zachary A. , Dixon, Rebekah E. , Marion, James F., Tomizawa, Yutaka , Mohapatra, Sonmoon , Charabaty, Aline , Lazarev, Mark , Figueroa, Esteban, Hanada, Yuri , Song, Louis M. Wong Kee , Wong Kee Song, Louis M, Nishimura, Makoto , Faleck, David M. , Yang, Dennis J. , D'Souza, Lionel S. , Jit, Simran, Parian, Alyssa M. , Wang, Andrew Y.

Mayo Clinic

Endoscopy International Open | April 14, 2022 | Volume: 10 | Issue: 04 | Pages: E354-E360

10.1055/a-1783-8756 | PMID 35433226 Get It

Abstract Background and study aims In patients with inflammatory bowel disease (IBD), endoscopically visible lesions with distinct borders can be considered for endoscopic resection. The role of endoscopic submucosal dissection (ESD) for these lesions is not well defined because of a paucity of data. We aimed to evaluate the outcomes of colorectal ESD of dysplastic lesions in patients with IBD across centers in the United States. Patients and methods This was a retrospective analysis of consecutive patients with IBD who were referred for ESD of dysplastic colorectal lesions at nine centers. The primary endpoints were the rates of en bloc resection and complete (R0) resection. The secondary endpoints were the rates of adverse events and lesion recurrence. Results A total of 45 dysplastic lesions (median size 30mm, interquartile range [IQR] 23 to 42 mm) in 41 patients were included. Submucosal fibrosis was observed in 73 %. En bloc resection was achieved in 43 of 45 lesions (96 %) and R0 resection in 34 of 45 lesions (76 %). Intraprocedural perforation occurred in one patient (2.4 %) and was treated successfully with clip placement. Delayed bleeding occurred in four patients (9.8 %). No severe intraprocedural bleeding or delayed perforation occurred. During a median follow-up of 18 months (IQR 13 to 37 months), local recurrence occurred in one case (2.6 %). Metachronous lesions were identified in 11 patients (31 %). Conclusions ESD, when performed by experts, is safe and effective for large, dysplastic colorectal lesions in patients with IBD. Despite the high prevalence of submucosal fibrosis, en bloc resection was achieved in nearly all patients with IBD undergoing ESD. Careful endoscopic surveillance is necessary to monitor for local recurrence and metachronous lesions after ESD.
Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data
Hansford, Jordan R. , Huang, Jie , Endersby, Raelene , Dodgshun, Andrew , Li, Bryan , Hwang, Eugene , Gajjar, Amar , Hoff, Katja von , Wells, Olivia, Wray, Alison, Kotecha, Rishi S. , Raleigh, David R. , Stoller, Schuyler , Mueller, Sabine , Bandopadhayay, Pratiti , Fouladi, Maryam , Onar‐Thomas, Arzu , Gottardo, Nicholas G. , Von Hoff, Katja , Mueller, Sabine , Schild, Steven E. , Fouladi, Maryam , Bouffet, Eric , Hansford, Jordan R , Leary, Sarah , Bouffet, Éric , Huang, Annie

Mayo Clinic

Neuro-Oncology Advances | April 14, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac056 | PMID 35664557 Get It

Abstract Background Pineoblastoma is a rare brain tumor usually diagnosed in children. Given its rarity, no pineoblastoma-specific trials have been conducted. Studies have included pineoblastoma accruing for other embryonal tumors over the past 30 years. These included only occasional children with pineoblastoma, making clinical features difficult to interpret and determinants of outcome difficult to ascertain. Patients and Methods Centrally or independently reviewed series with treatment and survival data from North American and Australian cases were pooled. To investigate associations between variables, Fisher’s exact tests, Wilcoxon-Mann-Whitney tests, and Spearman correlations were used. Kaplan-Meier plots, log-rank tests, and Cox proportional hazards models were used in survival analyses. Results We describe a pooled cohort of 178 pineoblastoma cases from Children’s Oncology Group (n = 82) and institutional series (n = 96) over 30 years. Children <3 years of age have significantly worse survival compared to older children, with 5-year progression-free survival (PFS) and overall survival (OS) estimates of 13.5 ± 5.1% and 16.2 ± 5.3%, respectively, compared with 60.8 ± 5.6% and 67.3 ± 5.0% for ≥3 years old (both P < .0001). Multivariable analysis showed male sex was associated with worse PFS in children <3 years of age (hazard ratio [HR] 3.93, 95% CI 1.80-8.55; P = .0006), suggestive of sex-specific risks needing future validation. For children ≥3 years of age, disseminated disease at diagnosis was significantly associated with an inferior 5-year PFS of 39.2 ± 9.7% (HR 2.88, 95% CI 1.52-5.45; P = .0012) and 5-year OS of 49.8 ± 9.1% (HR 2.87, 95% CI 1.49-5.53; P = .0016). Conclusion Given the rarity of this tumor, prospective, collaborative international studies will be vital to improving the long-term survival of these patients.